Rybelsus experiences: semaglutide as a tablet and what your blood shows

Rybelsus experiences depend more on how you take it than on the dose. Rybelsus contains semaglutide, the same substance as Ozempic, but as a tablet only a small fraction is absorbed. Take it wrong and it barely works.

That explains why the stories diverge so far: from fourteen kilos in four months to almost no effect.

The intake instructions are in the package leaflet, but rarely in the experience stories. To my mind that is exactly where the difference between a disappointment and a result sits.

What do Rybelsus users report?

Less appetite and a fuller stomach, comparable to the injections but usually milder. The complaints that come back most are nausea, diarrhoea, constipation and abdominal pain, concentrated in the first weeks of each dose step. Some users say they eventually switch to the injection.

The practical objection is almost never the tablet itself, but the ritual around it.

Timing matters. The Dutch Farmacotherapeutisch Kompas describes taking the tablet on an empty stomach with half a glass of water, at least thirty minutes before food, drink or other medicines. Swallow whole, do not break or chew.

What is the difference between Rybelsus, Ozempic and Wegovy?

The same active substance in three different forms and indications. Rybelsus is the daily tablet for type 2 diabetes, Ozempic the weekly injection for type 2 diabetes, and Wegovy the weekly injection with weight management as its registered indication. In the Netherlands Rybelsus is not registered for weight management.

The dose number says nothing about strength here. 14 mg as a tablet is not seven times as strong as 2 mg as an injection, because absorption works completely differently.

Does the tablet work as well as the injection?

For blood sugar close to equivalent, for weight loss less powerfully. In the PIONEER 4 trial oral semaglutide 14 mg produced an HbA1c reduction of 1.2% after 26 weeks, against 1.1% with liraglutide injection (Pratley et al., 2019).

At a much higher tablet dose that picture changes. In the OASIS 1 trial oral semaglutide 50 mg produced 15.1% weight loss after 68 weeks, against 2.4% on placebo (Knop et al., 2023). That is comparable to the 14.9% from the injection in STEP 1 (Wilding et al., 2021).

Note the difference: that 50 mg is not the dose Rybelsus is available in here.

The comparison between the injections sits in Ozempic or Mounjaro, and what users of the highest semaglutide dose report is covered in Wegovy experiences.

Which blood values move with Rybelsus?

The same ones as with the injection, because it is the same substance. Fasting glucose and fasting insulin respond fastest, often within two to four weeks. HbA1c follows after eight to twelve weeks, because it reflects an average over that period.

With Rybelsus there is one more reason to measure that does not apply to the injection.

If the values have not moved after three months, the first question is not whether the dose should go up, but whether the tablet is being taken correctly. A measurement makes that distinction visible; a scale does not.

Our GLP-1 three month check is built around that moment, assessed by a BIG-registered doctor.

What should you watch for during use?

The same signals as with the other GLP-1 drugs. Persistent severe abdominal pain radiating to the back is a reason to contact your GP, because the pancreas is a known point of attention with this drug class. The Dutch health information service Thuisarts advises always consulting your GP about new or persistent abdominal complaints during medication use.

The list of complaints, with what is measurable for each, sits in Ozempic side effects.

What strikes me about the Rybelsus stories is how many people conclude the drug does not work for them without ever checking whether they are taking it correctly.

If you notice little after three months, record your values before writing the drug off.

References

• Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019. PMID 31186120
• Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023. PMID 37385278
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185
• Farmacotherapeutisch Kompas, monograph for oral semaglutide (intake instructions and doses).
• Thuisarts, information on abdominal complaints during medication use.

Every blood test result includes a professional assessment from a BIG-registered doctor. For treatment decisions, discuss your results with your GP.